KalVista Reports Strong EKTERLY Revenue, Rapid Patient Adoption, and Cash Runway to Profitability

summarizeSummary

KalVista Pharmaceuticals reported $49.1 million in net product revenue for EKTERLY, demonstrating rapid patient adoption and strong commercial progress, and announced it expects current cash and projected revenues to fund operations through profitability.

check_boxKey Events

• Strong Product Revenue

  Reported $49.1 million in net product revenue for EKTERLY for the eight months ended December 31, 2025, following its US commercial launch in July 2025.

• Rapid Patient Adoption

  Achieved 1,702 patient start forms in the US through February 2026, covering almost 20% of the US HAE patient population, with 724 unique prescribers.

• Cash Runway to Profitability

  Anticipates current cash, cash equivalents, and marketable securities of $300.2 million as of December 31, 2025, along with projected EKTERLY revenues, will fund the company through profitability.

• International Expansion

  EKTERLY has launched in Japan through partner Kaken Pharmaceutical Co., Ltd., and is exhibiting similar adoption trends in Germany.

auto_awesomeAnalysis

This 8-K details KalVista's strong financial and commercial performance for its HAE treatment, EKTERLY. The company reported $49.1 million in net product revenue for the eight-month transition period, driven by rapid patient adoption with 1,702 patient start forms received in the US, representing nearly 20% of the patient population. A critical positive is the company's guidance that its current cash position of $300.2 million, combined with projected EKTERLY revenues, is expected to fund operations through profitability. This significantly de-risks the company's financial outlook. Additionally, KalVista provided positive updates on international launches and accelerated enrollment in its pediatric HAE trial, with new data expected soon.